GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MEX:GILD) » Definitions » Cyclically Adjusted Revenue per Share

Gilead Sciences (MEX:GILD) Cyclically Adjusted Revenue per Share : MXN460.11 (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Gilead Sciences's adjusted revenue per share for the three months ended in Mar. 2025 was MXN108.336. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN460.11 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted Revenue Growth Rate was 2.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Gilead Sciences was 47.20% per year. The lowest was 9.00% per year. And the median was 31.75% per year.

As of today (2025-05-10), Gilead Sciences's current stock price is MXN1910.62. Gilead Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN460.11. Gilead Sciences's Cyclically Adjusted PS Ratio of today is 4.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gilead Sciences was 21.39. The lowest was 2.68. And the median was 4.60.


Gilead Sciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted Revenue per Share Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 314.48 391.14 406.87 395.15 492.96

Gilead Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 395.30 449.49 473.41 492.96 460.11

Competitive Comparison of Gilead Sciences's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PS Ratio falls into.


;
;

Gilead Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=108.336/134.9266*134.9266
=108.336

Current CPI (Mar. 2025) = 134.9266.

Gilead Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 83.994 100.684 112.560
201509 93.259 100.392 125.340
201512 99.497 99.792 134.527
201603 95.018 100.470 127.604
201606 106.129 101.688 140.819
201609 108.302 101.861 143.458
201612 113.899 101.863 150.870
201703 92.790 102.862 121.715
201706 98.011 103.349 127.957
201709 89.598 104.136 116.090
201712 88.579 104.011 114.908
201803 70.028 105.290 89.740
201806 84.847 106.317 107.679
201809 80.087 106.507 101.457
201812 88.001 105.998 112.018
201903 79.845 107.251 100.449
201906 85.515 108.070 106.767
201909 87.320 108.329 108.759
201912 87.031 108.420 108.308
202003 102.433 108.902 126.912
202006 94.591 108.767 117.341
202009 115.220 109.815 141.568
202012 115.237 109.897 141.483
202103 104.035 111.754 125.607
202106 98.219 114.631 115.608
202109 120.912 115.734 140.963
202112 117.752 117.630 135.067
202203 103.973 121.301 115.652
202206 99.951 125.017 107.874
202209 112.331 125.227 121.032
202212 113.878 125.222 122.704
202303 90.797 127.348 96.201
202306 89.931 128.729 94.261
202309 97.695 129.860 101.507
202312 96.219 129.419 100.313
202403 88.984 131.776 91.111
202406 101.822 132.554 103.645
202409 118.472 133.029 120.162
202412 123.422 133.157 125.062
202503 108.336 134.927 108.336

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Gilead Sciences  (MEX:GILD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1910.62/460.11
=4.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gilead Sciences was 21.39. The lowest was 2.68. And the median was 4.60.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Gilead Sciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Industry
Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).